Medicines committee felt unable to recommend use of pentosan polyphosphate in vCJD

BMJ. 2003 Oct 4;327(7418):770. doi: 10.1136/bmj.327.7418.770-b.
No abstract available

Publication types

  • News

MeSH terms

  • Adolescent
  • Central Nervous System Agents / therapeutic use*
  • Creutzfeldt-Jakob Syndrome / drug therapy*
  • Humans
  • Pentosan Sulfuric Polyester / therapeutic use*

Substances

  • Central Nervous System Agents
  • Pentosan Sulfuric Polyester